Výsledky vyhledávání - "Thomas Perretti"

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia

Autor: Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim V. Ptushkin, Ana Marin-Niebla, Ramon García-Sanz, Steven Le Gouill, Anastasios Stathis, Alessia Bottos, Habib Hamidi, Pablo Katz, Thomas Perretti, Jenna C. Willis, Christian Buske

Publikováno v: Leukemia & lymphoma
Leukemia & lymphoma, 2022, pp.1-12. ⟨10.1080/10428194.2021.2015765⟩

International audience; We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba8f96d704415a7299eec0f3aafbe50
https://pubmed.ncbi.nlm.nih.gov/35045765

Zobrazit plný text záznamu

Plný text ve formátu HTML

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Autor: Marcin Wójtowicz, Gianluigi Reda, Robin Foà, Mehmet Turgut, Eugen Tausch, Sebastian Böttcher, Marlies E.H.M. Van Hoef, Thomas Perretti, Jens Kisro, Francesc Bosch, Osman Ilhan, Sue Robinson, Beatrice Mahe, Veronique Leblond, Dzhelil Osmanov, Eva Mikuskova, Stephan Stilgenbauer, Peter Trask

Publikováno v: British Journal of Haematology
British Journal of Haematology, Wiley, 2021, ⟨10.1111/bjh.17326⟩
Scientia

Summary The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first‐line (1L; fit and non‐fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36fd119698300a25c003d9a2e6aa91d

Zobrazit plný text záznamu

Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase IIa CROSSWALK-c Trial Evaluating the Efficacy of Crovalimab As Adjunct Treatment in the Prevention of Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)

Autor: Caterina P. Minniti, Pablo Bartolucci, Julia Ramos, Diane-Charlotte Imbs, Lucia De Franceschi, Nadiesh Balachandran, Thomas Perretti, Alexandre Sostelly, Michael U. Callaghan, Kenneth I. Ataga

Publikováno v: Blood. 138:3111-3111

Background SCD is a group of autosomal recessive red blood cell (RBC) disorders caused by a single point mutation in the β- globin gene, with either homozygous inheritance, or heterozygous co-inheritance with other pathogenic variants of the β-glob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::635a4db05b7463cd56846f076cb8603b
https://doi.org/10.1182/blood-2021-151222

Zobrazit plný text záznamu

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Autor: Thomas Perretti, Ana Marin Niebla, Monique S Tomiczek, Marlies E.H.M. Van Hoef, Christian Buske, Gayane Tumyan, Panayiotis Panayiotidis, Steven Le Gouill, Vadim V. Ptushkin, Andrey Zaritskey, Anastasios Stathis, Catherine Thieblemont, Ramón García-Sanz

Publikováno v: Blood. 136:2-3

Introduction:Treatment options for R/R MCL, MZL and WM are limited. New combinations are in development. A previous Phase Ib study evaluating atezolizumab (A) in combination with obinutuzumab (O) in patients (pts) with R/R NHL reported no new safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca657b33438cf33a52811dacb55bef6d
https://doi.org/10.1182/blood-2020-137087

Zobrazit plný text záznamu

POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Autor: Juan-Manuel Sancho, Andreas Viardot, Corinne Haioun, Thomas Perretti, Juana Hernandez, Matthew J. Matasar, Andrew McMillan

Publikováno v: Journal of Clinical Oncology. 38:TPS8070-TPS8070

TPS8070 Background: The antibody-drug conjugate polatuzumab vedotin (pola; POLIVY) targets CD79b on B-cell malignancies. Pola plus bendamustine and rituximab (BR) has significantly improved efficacy vs BR alone in patients (pts) with R/R DLBCL. As a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6649cba0386bd3a103427a7f71e9e413
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8070

Zobrazit plný text záznamu

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

Autor: Juana Hernandez, Andreas Viardot, Andrew McMillan, Thomas Perretti, Matthew J. Matasar, Juan-Manuel Sancho, Corinne Haioun

Publikováno v: Blood. 134:5317-5317

Introduction: The antibody-drug conjugate polatuzumab vedotin (pola) targets CD79b on B-cell malignancies. Pola in combination with bendamustine and rituximab (BR) improved complete response (CR) rate and overall survival (OS) in patients with relaps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0b3aa2e729bef9079c4e179af71cf96
https://doi.org/10.1182/blood-2019-123673

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání